Structural analysis of the HIT immune complex
Structural analysis of the HIT immune complex
批准号:
8945196
负责人:
Zheng Cai
金额:
$40.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2020-03-31
关键词:
AdhesionsAntibodiesAntigen-Antibody ComplexAntigensAutoantibodiesAutoimmune DiseasesBindingBlood PlateletsCellsCessation of lifeClinicalClinical ResearchCollagenComplexDataDevelopmentDiagnosisDiagnostic ProcedureDiseaseEndothelial CellsEnzyme-Linked Immunosorbent AssayEpitopesFc ReceptorFutureGenerationsGlycosaminoglycansHemostatic AgentsHeparinHumanIgG4Immune responseIn VitroIndividualKnowledgeLaser injuryLeadLinkLow-Molecular-Weight HeparinMeasuresMediatingMethodsModelingMonoclonal AntibodiesMusOperative Surgical ProceduresPathogenesisPatientsPlatelet ActivationPlatelet Factor 4Pre-Clinical ModelPreparationPrevalenceProcessProteinsRecurrenceRiskSerologicalSolutionsStructural ModelsStructureSurfaceSystemTestingTherapeuticThrombinThrombocytopeniaThromboembolismThrombosisVenous Thrombosisbasedimerfondaparinuxhumanized antibodyimprovedin vivo Modellimb amputationmonocytemonomermutantnovelnovel diagnosticspreventpublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): HIT is a severe autoimmune disorder that predisposes to arterial and venous thrombosis. HIT is notable for several reasons, including the remarkable prevalence of otherwise immunologically healthy individuals exposed to heparin who develop self-reactive antibodies to a normal host protein, PF4, when it is released following platelet activation. Current clinical challenges in HIT include over-diagnosis and over-treatment and well as the risks of anticoagulating patients with thrombocytopenia and other hemostatic challenges such as recent surgery. In this proposed study, we will try to obtain in-depth understanding of the pathogenic ternary complex using crystallographic studies. We will try to expand our understanding of the PF4 tetramerization process and the creation of a novel type of antigenic epitope. We will try to develop a panel of PF4 mutants in different states of oligomerization that may provide a more reliable diagnostic method. We will also humanize RTO, maintain its PF4-monomer binding ability, but minimize the human immune response in preparation for potential future clinical studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金